Virtus ETF Advisers’s DICE Therapeutics, Inc. Common Stock DICE Stock Holding History

Virtus ETF Advisers’s Portfolio DICE Stock Details DICE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-3,166	Closed	-$147K	–	485
2023 Q2	$147K	Buy	3,166 +186	+6%	+$6.43K	0.09%	321
2023 Q1	$85.4K	Sell	2,980 -1,147	-28%	-$34K	0.05%	377
2022 Q4	$129K	Sell	4,127 -3,413	-45%	-$111K	0.07%	393
2022 Q3	$153K	Buy	7,540 +58	+0.8%	+$1.06K	0.06%	350
2022 Q2	$116K	Buy	7,482 +1,166	+18%	+$20.1K	0.04%	395
2022 Q1	$121K	Sell	6,316 -367	-5%	-$6.55K	0.05%	268
2021 Q4	$169K	Buy	+6,683	New	+$196K	0.06%	294

Virtus ETF Advisers's DICE Position: Q3 2023 in Review

Virtus ETF Advisers sold out of DICE Therapeutics, Inc. Common Stock (DICE) in Q3 2023, closing a stake of 3,166 shares — an estimated $147K sold.

Virtus ETF Advisers first reported a position in DICE in Q4 2021 and held it in 7 quarters. The position peaked at $169K in Q4 2021. 0 funds tracked by Wall St. Rank hold DICE as of Q3 2023.

Virtus ETF Advisers reported no remaining DICE Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Virtus ETF Advisers sold 3,166 DICE Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $147K.
Virtus ETF Advisers first reported a position in DICE Therapeutics, Inc. Common Stock in Q4 2021 and held it in 7 quarters.
Virtus ETF Advisers's DICE Therapeutics, Inc. Common Stock position peaked at $169K in Q4 2021.
0 funds tracked by Wall St. Rank held DICE Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Virtus ETF Advisers's 13F filing for Q3 2023, filed 7 Nov 2023.